Treatment Patterns of Neratinib in HER2+ EBC in China
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neratinib
Sponsor: Pierre Fabre Medicament